Madrigal Pharmaceuticals reported a 50% year-over-year increase in Q3 net sales, driven by strong demand for its drug Rezdiffra, approved for treating metabolic liver disease. Despite this positive performance and Rezdiffra's growing market penetration in a rapidly expanding field, the company's shares fell about 8% following earnings, possibly due to a whistleblower disclosure. The drug holds significant long-term growth potential with patent protection until 2045, supported by a robust pipeline and first-mover advantage. However, investors should watch for competitive and legal risks moving forward.
Madrigal Pharmaceuticals' Q3 earnings news comes as 106 of 150 health-sector US stocks tradable on Pluang rose today. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 23:12 WIB: Tilray Brands Inc (TLRY) gained 11.32% to USD 2.95 with a typical hold time of 32 days and 96% sell order activity; Nuwellis Inc (NUWE) dropped 10.15% to USD 5.31 with 100% sell orders; Moderna, Inc. (MRNA) rose 9.60% to USD 250.38 with 76% sell orders and a typical hold time of 58 days.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
